Fabrício Freire de Melo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fabrício Freire de Melo has a total of 473 co-authors. Here are the top co-authors by number of shared publications:
Maria Luísa Cordeiro Santos
Multidisciplinary Health Institute, Federal University of Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
25 shared publicationsHanna Santos Marques
Campus Vitória da Conquista, Universidade Estadual do Sudoeste da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
24 shared publicationsMarcel Silva Luz
Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
24 shared publicationsBreno Bittencourt de Brito
Multidisciplinary Health Institute, Federal University of Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
22 shared publicationsFabian Fellipe Bueno Lemos
22 shared publicationsFilipe Antônio França da Silva
Multidisciplinary Health Institute, Federal University of Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
22 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Unified Journals Network Publishing House in Revista Multidisciplinar do Nordeste Mineiro
- Vol. 13 (21) , 1-30
Modulation of Aedes Midgut Microbiota by Dengue Virus Serotypes: A Review of Host-Pathogen-Microbiome Interactions
The Aedes aegypti midgut microbiota serves as a critical determinant of vector competence, modulating immune and metabolic responses to Dengue virus (DENV). Viral infection precipitates distinct ecological shifts within this environment, challenging the stability of the bacterial “core” against blood-meal induced dysbiosis. These microbial dynamics are shaped by a complex interplay between viral serotypes, time post-infection, mosquito physiological status, blood-meal source, and experimental conditions. While the basal core often persists, specific bacterial families have been reported to show serotype-associated fluctuations and may represent candidate correlates of viral susceptibility or resistance. Elucidating these host-pathogen-microbiome interactions is essential for defining biological barriers to transmission. This narrative review synthesizes current evidence on the modulation of the mosquito microbiome by DENV serotypes 1-4, highlighting ecological nuances and identifying bacterial taxa and mechanisms that warrant further investigation as potential targets for microbiome-based vector control.
- 1 October 2026
- Published by Unified Journals Network Publishing House in Revista Multidisciplinar do Nordeste Mineiro
- Vol. 13 (21) , 1-30
Open AccessModulation of Aedes Midgut Microbiota by Dengue Virus Serotypes: A Review of Host-Pathogen-Microbiome Interactions
The Aedes aegypti midgut microbiota serves as a critical determinant of vector competence, modulating immune and metabolic responses to Dengue virus (DENV). Viral infection precipitates distinct ecological shifts within this environment, challenging the stability of the bacterial “core” against blood-meal induced dysbiosis. These microbial dynamics are shaped by a complex interplay between viral serotypes, time post-infection, mosquito physiological status, blood-meal source, and experimental conditions. While the basal core often persists, specific bacterial families have been reported to show serotype-associated fluctuations and may represent candidate correlates of viral susceptibility or resistance. Elucidating these host-pathogen-microbiome interactions is essential for defining biological barriers to transmission. This narrative review synthesizes current evidence on the modulation of the mosquito microbiome by DENV serotypes 1-4, highlighting ecological nuances and identifying bacterial taxa and mechanisms that warrant further investigation as potential targets for microbiome-based vector control.
- Open Access
- 1 September 2026
- Published by AME Publishing Company in Gynecology and Pelvic Medicine
- Vol. 9, 35
Gynecologic management of cervical cancer patients undergoing immunotherapy: an up-to-date narrative review
Background and Objective: Cervical cancer (CC) remains a significant global health challenge, especially in low and middle-income countries. The advent of immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 agents, has introduced promising therapeutic options for advanced and recurrent cases. However, gynecologic management during immunotherapy is poorly characterized, particularly regarding structured pre-treatment evaluation, integrated oncology-gynecology surveillance, timed contraception and fertility preservation, management of immune-mediated genital-tract fistulas (GTFs), and evidence-based approaches to pregnancy planning and endocrine dysfunction. This narrative review synthesizes evidence on gynecologic management of CC patients receiving immunotherapy, clinical decision frameworks, and identifies knowledge gaps requiring further investigation. Methods: A structured search was performed in PubMed, Web of Science, and the Cochrane Library (January 2015–October 2025) using MeSH terms and keywords for cervical cancer, immunotherapy, ICIs, gynecologic management, and fertility or pregnancy. Only original articles, case reports, guidelines, and reviews in English or Spanish were included. References were supplemented by artificial intelligence (AI)-based retrieval using SciSpace, OpenEvidence, and Perplexity Pro; deduplication ensured AI-derived citations were only retained as “AI-supplementary” when not present in database searches. ChatGPT-5 Thinking was applied solely for English translation and technical editing, with no generative content added to scientific findings. Key Content and Findings: While ICIs (e.g., nivolumab, pilinumab, tisotumab, pembrolizumab, cemiplimab) have improved outcomes for advanced or metastatic CC, specific guidance for gynecologic management remains limited. Findings show that standard gynecologic screenings [human papillomavirus (HPV), cytology] proceed unchanged but should be aligned with oncology visits. Fertility preservation, via oocyte/embryo cryopreservation, and highly effective contraception are essential before, during, and after therapy. ICIs are discouraged during pregnancy; if pregnancy is detected, treatment should be interrupted. Proactive surveillance for immune-related adverse events (irAEs), including the emerging risk of GTF is crucial, especially within the first 6–8 weeks. Conclusions: Immunotherapy advances care for recurrent/metastatic CC but gynecologic management remains insufficiently addressed. Evidence for fertility counseling, reproductive monitoring, and managing gynecologic irAEs is fragmented. This review underscores the need for interdisciplinary oncology-gynecology coordination, clearer practice protocols, and future research focused on women of reproductive age undergoing ICIs.
- 1 September 2026
- Published by AME Publishing Company in Gynecology and Pelvic Medicine
- Vol. 9, 35
Open AccessGynecologic management of cervical cancer patients undergoing immunotherapy: an up-to-date narrative review
Background and Objective: Cervical cancer (CC) remains a significant global health challenge, especially in low and middle-income countries. The advent of immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 agents, has introduced promising therapeutic options for advanced and recurrent cases. However, gynecologic management during immunotherapy is poorly characterized, particularly regarding structured pre-treatment evaluation, integrated oncology-gynecology surveillance, timed contraception and fertility preservation, management of immune-mediated genital-tract fistulas (GTFs), and evidence-based approaches to pregnancy planning and endocrine dysfunction. This narrative review synthesizes evidence on gynecologic management of CC patients receiving immunotherapy, clinical decision frameworks, and identifies knowledge gaps requiring further investigation. Methods: A structured search was performed in PubMed, Web of Science, and the Cochrane Library (January 2015–October 2025) using MeSH terms and keywords for cervical cancer, immunotherapy, ICIs, gynecologic management, and fertility or pregnancy. Only original articles, case reports, guidelines, and reviews in English or Spanish were included. References were supplemented by artificial intelligence (AI)-based retrieval using SciSpace, OpenEvidence, and Perplexity Pro; deduplication ensured AI-derived citations were only retained as “AI-supplementary” when not present in database searches. ChatGPT-5 Thinking was applied solely for English translation and technical editing, with no generative content added to scientific findings. Key Content and Findings: While ICIs (e.g., nivolumab, pilinumab, tisotumab, pembrolizumab, cemiplimab) have improved outcomes for advanced or metastatic CC, specific guidance for gynecologic management remains limited. Findings show that standard gynecologic screenings [human papillomavirus (HPV), cytology] proceed unchanged but should be aligned with oncology visits. Fertility preservation, via oocyte/embryo cryopreservation, and highly effective contraception are essential before, during, and after therapy. ICIs are discouraged during pregnancy; if pregnancy is detected, treatment should be interrupted. Proactive surveillance for immune-related adverse events (irAEs), including the emerging risk of GTF is crucial, especially within the first 6–8 weeks. Conclusions: Immunotherapy advances care for recurrent/metastatic CC but gynecologic management remains insufficiently addressed. Evidence for fertility counseling, reproductive monitoring, and managing gynecologic irAEs is fragmented. This review underscores the need for interdisciplinary oncology-gynecology coordination, clearer practice protocols, and future research focused on women of reproductive age undergoing ICIs.
- Open Access
- 4 June 2026
- Published by Unified Journals Network Publishing House in Revista Multidisciplinar do Nordeste Mineiro
- Vol. 13 (12) , 1-31
ASSOCIAÇÃO ENTRE INTERLEUCINAS 1β, 6 E 8 E A CONDIÇÃO PÓS-COVID: UMA REVISÃO SISTEMÁTICA COM METANÁLISE E ANÁLISE EXPLORATÓRIA DE FATORES DE RISCO
A condição pós-COVID (CPC) caracteriza-se pela persistência de sintomas após a infecção aguda por SARS-CoV-2, sendo associada a mecanismos inflamatórios sustentados. Esta revisão sistemática com metanálise avaliou os níveis de IL-1β, IL-6 e IL-8 em indivíduos com CPC, comparando-os a controles saudáveis e indivíduos recuperados sem sintomas persistentes. O protocolo foi registrado no PROSPERO (CRD42024610712) e conduzido conforme as diretrizes PRISMA 2020. Foram incluídos estudos observacionais que avaliaram concentrações séricas ou plasmáticas dessas citocinas. A qualidade metodológica foi analisada por instrumentos validados, e a diferença média padronizada (SMD) com IC95% foi estimada por modelos de efeitos fixos ou aleatórios. Vinte e cinco estudos, totalizando 3.927 participantes, foram incluídos. Indivíduos com CPC apresentaram níveis significativamente mais elevados de IL-1β, IL-6 e IL-8 em comparação a controles saudáveis. Em comparação a indivíduos recuperados, apenas a IL-1β permaneceu significativamente elevada. As análises apresentaram heterogeneidade de moderada a elevada entre os desfechos. Análises de subgrupo sugeriram influência da idade e da gravidade da infecção aguda. Os achados sustentam a hipótese de inflamação persistente na CPC, destacando a IL-1β como potencial biomarcador associado à persistência sintomática.
- 4 June 2026
- Published by Unified Journals Network Publishing House in Revista Multidisciplinar do Nordeste Mineiro
- Vol. 13 (12) , 1-31
Open AccessASSOCIAÇÃO ENTRE INTERLEUCINAS 1β, 6 E 8 E A CONDIÇÃO PÓS-COVID: UMA REVISÃO SISTEMÁTICA COM METANÁLISE E ANÁLISE EXPLORATÓRIA DE FATORES DE RISCO
A condição pós-COVID (CPC) caracteriza-se pela persistência de sintomas após a infecção aguda por SARS-CoV-2, sendo associada a mecanismos inflamatórios sustentados. Esta revisão sistemática com metanálise avaliou os níveis de IL-1β, IL-6 e IL-8 em indivíduos com CPC, comparando-os a controles saudáveis e indivíduos recuperados sem sintomas persistentes. O protocolo foi registrado no PROSPERO (CRD42024610712) e conduzido conforme as diretrizes PRISMA 2020. Foram incluídos estudos observacionais que avaliaram concentrações séricas ou plasmáticas dessas citocinas. A qualidade metodológica foi analisada por instrumentos validados, e a diferença média padronizada (SMD) com IC95% foi estimada por modelos de efeitos fixos ou aleatórios. Vinte e cinco estudos, totalizando 3.927 participantes, foram incluídos. Indivíduos com CPC apresentaram níveis significativamente mais elevados de IL-1β, IL-6 e IL-8 em comparação a controles saudáveis. Em comparação a indivíduos recuperados, apenas a IL-1β permaneceu significativamente elevada. As análises apresentaram heterogeneidade de moderada a elevada entre os desfechos. Análises de subgrupo sugeriram influência da idade e da gravidade da infecção aguda. Os achados sustentam a hipótese de inflamação persistente na CPC, destacando a IL-1β como potencial biomarcador associado à persistência sintomática.
- Open Access
- 26 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 18 (1)
Cardiovascular burden of long coronavirus disease: Clinical challenges and emerging biomarkers
Long coronavirus disease (LC) is a condition characterized by a persistent state, with recurrent/remitting or progressive episodes, that may affect one or multiple organ systems following severe acute respiratory syndrome coronavirus 2 infection. The cardiovascular system is particularly impacted by this condition. This review aims to discuss the cardiovascular implications in LC and its potential mechanisms. We offer an updated summary of established and emerging biomarkers with clinical potential for diagnosis, risk stratification, and therapy monitoring. Conventional markers with established clinical roles, such as cardiac troponins, natriuretic peptides (B-type natriuretic peptide/N-terminal pro-B-type natriuretic peptide), D-dimer, and inflammatory markers (e.g. , C-reactive protein, interleukin-6), coexist with less established but promising biomarkers, such as growth differentiation factor-15, galectin-3, von Willebrand factor, endothelin-1, and circulating microRNAs. The incomplete understanding of the mechanisms and their diverse clinical manifestations, underscores the urgent need for efficient diagnostic tests and predictive models. In this context, besides the lack of standardization in biomarker testing and the absence of validated longitudinal predictive models, the use of biomarker-based strategies represents a potential tool to improve early detection of high-risk patients, enable personalized follow-up, and support more effective prevention of cardiovascular complications in LC patients in clinical practice.
- 26 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 18 (1)
Open AccessCardiovascular burden of long coronavirus disease: Clinical challenges and emerging biomarkers
Long coronavirus disease (LC) is a condition characterized by a persistent state, with recurrent/remitting or progressive episodes, that may affect one or multiple organ systems following severe acute respiratory syndrome coronavirus 2 infection. The cardiovascular system is particularly impacted by this condition. This review aims to discuss the cardiovascular implications in LC and its potential mechanisms. We offer an updated summary of established and emerging biomarkers with clinical potential for diagnosis, risk stratification, and therapy monitoring. Conventional markers with established clinical roles, such as cardiac troponins, natriuretic peptides (B-type natriuretic peptide/N-terminal pro-B-type natriuretic peptide), D-dimer, and inflammatory markers (e.g. , C-reactive protein, interleukin-6), coexist with less established but promising biomarkers, such as growth differentiation factor-15, galectin-3, von Willebrand factor, endothelin-1, and circulating microRNAs. The incomplete understanding of the mechanisms and their diverse clinical manifestations, underscores the urgent need for efficient diagnostic tests and predictive models. In this context, besides the lack of standardization in biomarker testing and the absence of validated longitudinal predictive models, the use of biomarker-based strategies represents a potential tool to improve early detection of high-risk patients, enable personalized follow-up, and support more effective prevention of cardiovascular complications in LC patients in clinical practice.
- Open Access
- 24 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 17 (1)
Immune landscape of melanoma: Tumor microenvironment, resistance mechanisms, and predictive biomarkers
Melanoma, a highly immunogenic malignancy, has become a paradigm for immune-based therapies. Despite remarkable responses to immune checkpoint inhibitors, many patients exhibit primary or acquired resistance. These outcomes are largely driven by the composition and dynamics of the tumor microenvironment, which shape immune activation, suppression, and therapeutic responsiveness, contributing to immune escape. Moreover, checkpoint molecule expression, altered antigen presentation, and immunosuppressive cytokine profiles further hinder effective immune surveillance. Advances in biomarker discovery have provided valuable insights into predicting therapy response and guiding individualized treatment. This review discusses the interplay between melanoma and its immune microenvironment, explores mechanisms of immune resistance, and highlights emerging predictive biomarkers with potential to refine clinical decision-making and improve outcomes.
- 24 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 17 (1)
Open AccessImmune landscape of melanoma: Tumor microenvironment, resistance mechanisms, and predictive biomarkers
Melanoma, a highly immunogenic malignancy, has become a paradigm for immune-based therapies. Despite remarkable responses to immune checkpoint inhibitors, many patients exhibit primary or acquired resistance. These outcomes are largely driven by the composition and dynamics of the tumor microenvironment, which shape immune activation, suppression, and therapeutic responsiveness, contributing to immune escape. Moreover, checkpoint molecule expression, altered antigen presentation, and immunosuppressive cytokine profiles further hinder effective immune surveillance. Advances in biomarker discovery have provided valuable insights into predicting therapy response and guiding individualized treatment. This review discusses the interplay between melanoma and its immune microenvironment, explores mechanisms of immune resistance, and highlights emerging predictive biomarkers with potential to refine clinical decision-making and improve outcomes.
- Open Access
- 22 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pathophysiology
- Vol. 16 (4)
Update on the pathogenesis and clinical management of Helicobacter pylori gastric infection and associated diseases
Helicobacter pylori (H. pylori ) is a gram-negative, spiral-shaped, microaerophilic bacterium that infects over 43% of the global population, with higher prevalence in regions of low socioeconomic status and poor sanitation. It is transmitted mainly through oral-oral and fecal-oral routes and has evolved multiple mechanisms that allow colonization of the acidic gastric environment, including urease production, chemotaxis, and a variety of adhesins. The bacterium expresses several virulence factors that enhance its pathogenicity, such as cytotoxin-associated antigen A, vacuolating cytotoxin A, and the small regulatory RNA NikS, found to be essential for the fine-tuning of the bacterial virulence. Although many infected individuals remain asymptomatic, H. pylori infection is associated with multiple clinical outcomes, including chronic gastritis, peptic ulcers, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma, all correlated to the host immune response and chronic inflammation. Diagnosis relies on both invasive and non-invasive methods, and growing antibiotic resistance poses a major challenge to treatment. New therapeutic strategies, such as tailored therapy, potassium-competitive acid blockers, and probiotics are under investigation. Vaccine development remains a key area of research, with several candidates currently in preclinical and clinical evaluation.
- 22 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pathophysiology
- Vol. 16 (4)
Open AccessUpdate on the pathogenesis and clinical management of Helicobacter pylori gastric infection and associated diseases
Helicobacter pylori (H. pylori ) is a gram-negative, spiral-shaped, microaerophilic bacterium that infects over 43% of the global population, with higher prevalence in regions of low socioeconomic status and poor sanitation. It is transmitted mainly through oral-oral and fecal-oral routes and has evolved multiple mechanisms that allow colonization of the acidic gastric environment, including urease production, chemotaxis, and a variety of adhesins. The bacterium expresses several virulence factors that enhance its pathogenicity, such as cytotoxin-associated antigen A, vacuolating cytotoxin A, and the small regulatory RNA NikS, found to be essential for the fine-tuning of the bacterial virulence. Although many infected individuals remain asymptomatic, H. pylori infection is associated with multiple clinical outcomes, including chronic gastritis, peptic ulcers, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma, all correlated to the host immune response and chronic inflammation. Diagnosis relies on both invasive and non-invasive methods, and growing antibiotic resistance poses a major challenge to treatment. New therapeutic strategies, such as tailored therapy, potassium-competitive acid blockers, and probiotics are under investigation. Vaccine development remains a key area of research, with several candidates currently in preclinical and clinical evaluation.
- Open Access
- 6 August 2025
- Published by Universidade Federal de Pelotas in Journal of Nursing and Health
- Vol. 15 (3) , e1529289
Internações de crianças por dengue na Bahia: uma análise epidemiológica
Objetivo: descrever a prevalência de internações por dengue clássica na população pediátrica da Bahia no período entre 2019 e 2023, em comparação com o contexto nacional e regional em que o estado está inserido. Método: estudo ecológico em dados secundários obtidos no Sistema de Informações Hospitalares e Sistema de Informação de Agravos de Notificação, referentes às internações por dengue na Bahia. Resultados: foram registradas 58.080 internações por dengue na população de zero a 19 anos do Brasil, 37,11% delas na região Nordeste, com predominância na Bahia (22,92%). A internação teve duração média de 3,1 dias. Crianças e adolescentes representaram 46,86% das internações por dengue clássica no Estado, com maior acometimento de meninos (54,22%) e indivíduos negros (76,66%). Conclusão: a dengue impacta significativamente a população pediátrica da Bahia, reforçando a necessidade imperiosa de uma abordagem de gestão integrada para prevenção e controle da doença.
- 6 August 2025
- Published by Universidade Federal de Pelotas in Journal of Nursing and Health
- Vol. 15 (3) , e1529289
Open AccessInternações de crianças por dengue na Bahia: uma análise epidemiológica
Objetivo: descrever a prevalência de internações por dengue clássica na população pediátrica da Bahia no período entre 2019 e 2023, em comparação com o contexto nacional e regional em que o estado está inserido. Método: estudo ecológico em dados secundários obtidos no Sistema de Informações Hospitalares e Sistema de Informação de Agravos de Notificação, referentes às internações por dengue na Bahia. Resultados: foram registradas 58.080 internações por dengue na população de zero a 19 anos do Brasil, 37,11% delas na região Nordeste, com predominância na Bahia (22,92%). A internação teve duração média de 3,1 dias. Crianças e adolescentes representaram 46,86% das internações por dengue clássica no Estado, com maior acometimento de meninos (54,22%) e indivíduos negros (76,66%). Conclusão: a dengue impacta significativamente a população pediátrica da Bahia, reforçando a necessidade imperiosa de uma abordagem de gestão integrada para prevenção e controle da doença.
- Open Access
- 15 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (6) , 104706
Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease
The global prevalence of diabetes has surged in recent years, with diabetic kidney disease (DKD) emerging as a major complication. Traditional therapies have had limited success in slowing progression to end-stage kidney disease. However, novel therapies, particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, which were initially developed for hyperglycemia management, have transformed the treatment of obesity, heart failure, cardiovascular disease, and more recently, DKD. SGLT2 inhibitors have consistently and significantly reduced cardiovascular events, albuminuria, and glomerular filtration rate, highlighting their efficacy across diverse clinical presentations for patients with kidney impairment. Although fewer studies have specifically investigated GLP-1 receptor agonists in patients with kidney disease, existing evidence underscores their potential to slow renal disease progression, reduce albuminuria, and improve clinically relevant outcomes. However, further research is needed to better identify patients most likely to benefit from treatment. Together, these therapies represent valuable advancements for DKD, offering significant reductions in morbidity and mortality and shifting the management of the disease by becoming essential pillars for the treatment of these patients.
- 15 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (6) , 104706
Open AccessBeyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease
The global prevalence of diabetes has surged in recent years, with diabetic kidney disease (DKD) emerging as a major complication. Traditional therapies have had limited success in slowing progression to end-stage kidney disease. However, novel therapies, particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, which were initially developed for hyperglycemia management, have transformed the treatment of obesity, heart failure, cardiovascular disease, and more recently, DKD. SGLT2 inhibitors have consistently and significantly reduced cardiovascular events, albuminuria, and glomerular filtration rate, highlighting their efficacy across diverse clinical presentations for patients with kidney impairment. Although fewer studies have specifically investigated GLP-1 receptor agonists in patients with kidney disease, existing evidence underscores their potential to slow renal disease progression, reduce albuminuria, and improve clinically relevant outcomes. However, further research is needed to better identify patients most likely to benefit from treatment. Together, these therapies represent valuable advancements for DKD, offering significant reductions in morbidity and mortality and shifting the management of the disease by becoming essential pillars for the treatment of these patients.
- Open Access
- 1 June 2025
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 3, 27
Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer
Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer
- 1 June 2025
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 3, 27
Open AccessEradication of Helicobacter pylori and its impact on the incidence of gastric cancer
Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer